Mehdizadeh, M., Aguilar, M., Thorin, E., Ferbeyre, G
(2023), New England Journal of Medicine 389(6), DOI 10.1056/NEJMoa2301972 Statistics from clinical literature Developer: Eli Lilly and Company , code name LY3437943 Mechanism: triple agonist acting at GLP-1 , GIP and glucagon receptors, the first such peptide in advanced clinical development Phase 2 obesity trial (NEJM 2023) results at 12 mg/week dose, n=338: 24.2 % mean reduction in body weight at 48 weeks 25.8 % loss of body fat (DEXA) 9.7 % reduction in hemoglobin A1c in prediabetic patients Phase 2 type 2 diabetes trial (Lancet 2023): 2.02 % point A1c reduction at 36 weeks vs
But this is another area where you should be careful what you order and lean on the nutritional info on the Starbucks website or in the store
There were no claims for HCPSC code C9760 in CY 2024